Lymphocyte function-associated antigen-1 antagonist - Bristol-Myers Squibb
Alternative Names: BMS 587101; LFA-1 antagonist - Bristol-Myers SquibbLatest Information Update: 10 Jul 2007
At a glance
- Originator Bristol-Myers Squibb; Cerep
- Class Small molecules
- Mechanism of Action Lymphocyte function-associated antigen-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
- Discontinued Autoimmune disorders; Psoriasis
Most Recent Events
- 06 Apr 2006 Phase-II clinical trials in Inflammation in USA (PO)
- 24 Nov 2004 Phase-I clinical trials in Autoimmune disorders in USA (PO)
- 24 Nov 2004 Phase-I clinical trials in Inflammation in USA (PO)